univers coverag
calendar event
regulatori event pdufa dova avatrombopag thrombocytopenia chronic liver
societi neurolog surgeon world feder hemophilia
link
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
bottom line last week boston biopharma bu tour brought togeth manag
team investor discuss recent develop key controversi number
compani stock within therapeut coverag univers compani includ
tsro accompani page detail discuss result
meet import takeaway event
assum coverag switch makena success drive intrarosa
use wacc termin growth rate
bottom line assum coverag colleagu schwartz
market perform rate price target biopharmaceut compani primarili focus
women iron anemia market compani three primari revenu driver
report sale compris makena hydroxyprogesteron caproat inject
reduc risk pre-term birth sale ferahem ferumoxytol inject patient
iron defici anemia sale cord blood registri cbr sale
ytd stock posit regulatori decis februari around ferahem
label expans makena subq welcom surpris given setback past
year manag execut well base busi prioriti also brought two growth
driver acquisit intrarosa prasteron treatment moder sever
dyspareunia bremelanotid hypoact sexual desir disord help off-set potenti eros
intramuscular im makena gener expect day ferahem settlement
sandoz sale like declin mid-doubl digit next two year believ
new growth driver sale return believ
appropri reflect stock current level note busi develop potenti
bring addit women health asset remain prioriti manag anticip larg
deal anytim soon given forecast leverag ratio overal see
key execut year build upon recent win look greater insight two key
debat makena im gener come much share makena subq hold onto
peak potenti intrarosa product captur signific share crowd
dyspareunia/vulvovagin atrophi vva market believ current level uncertainti
around franchis appropri reflect stock thu assum coverag market
littl doubt makena sq present usag advantag im formul uncertain much
share sq keep lower cost im gener reach market
intrarosa good start remain seen drive sale non-prescript
bremelanotid offer improv valu proposit versu competit howev medacorp physician
bottom line report bid evhc amsurg busi view
synergist hca ambulatori platform consist unit primari care
clinic accord reuter op bid privat equiti firm kkr would acquir
evhc physician servic asset legaci amsurg busi evhc nr approxim
revenu mm ebitda servic line primarili skew toward gi multi-specialti
ophthalmolog complement asc gi center estim amsurg busi
evhc purchas price around ev expect could fund mix
cash debt estim balanc sheet flexibl
leverag view compani expand altern access point best posit
see multipl expans due increas weight higher multipl ambulatori asset
sotp basi see valuat rang
bid evhc amsurg busi kkr would acquir evhc physician servic
view amsurg synergist hca ambulatori platform consist unit primari
amsurg oper asc revenu mm ebitda
estim purchas price around ev expect could fund
mix cash debt
transact could gener mm synergi year post close geograph fl tx ca
busi segment overlap exhibit
view compani expand altern access point best posit see
multipl expans due increas weight higher multipl ambulatori asset
reuter articl highlight potenti bid evhc amsurg avail follow link
new ceo highlight commerci organ improv top
bottom line fri group analyst meet set met cfo vaseem
mahboob elgx newli appoint ceo john onopchenko discuss yield new
news regard financi outlook intra-qtr busi trend rather primarili opportun
ceo onopchenko share prioriti vision regard plan approach turnaround
elgx commerci organ left interact hope leadership chang
may portend improv execut go forward -- -come period deceler growth trend
multipl regulatory/fda setback although compani control
encourag view elgx recent reiter guidanc addt downward estimate revis
result indic busi may stabil howev also continu believ us
afx soft weak nellix sale limit sales/ep upsid potenti -- -like remain extend
overhang stock -- -over intermedi term item new ceo fix overnight
also still see elgx catalyst growth re-acceler weight
see rush share reiter mp rate price target
remind john onopchenko move ceo seat may follow brief stent elgx
mr onopchenko focus quality/production/clin initi remain
confid improv come take time
ceo onopchenko focu heavili eglx commerci oper laid
key prioriti area still need time evalu reflect organ settl
unveil street final aspect turnaround strategi implement
top-to-bottom review sale strategi sell organ alreadi underway
bottom line investor could nervou morn due arql file resal
prospectu market close pontifax sphera purchas million
prefer stock privat placement last novemb prefer stock convert automat
common stock may result arql sharehold approv annual meet
amend certif incorpor increas arql author common stock
automat convers built origin stock purchas agreement last novemb
pipe agreement also requir arql file resal registr statement regist
resal common stock convers henc file importantli would highlight
convers file pre-arrang part placement last novemb addit
spoke arql manag indic evid pontifax sphera
plan sell type registr statement common virtual pipe
transact continu view arql stock well posit long-term appreci arq
revers btk inhibitor becom de-risk clinic updat next arq clinic
updat arql expect next month european hematolog associ eha
meaning updat includ earli efficaci expect american societi hematolog
later year reiter op
bottom line report provid updat week end may key gener
product watch
weekli iqvia im trend week end may
posit deal follow puls call anti-trust specialist
asco abstract highlight opportun colorect cancer
eha abstract provid increment stomp updat dlbcl data
 methodolog averag dcf price-to-earnings p/sale
ped confirmatori data eu po alreadi incorpor
recap well-fund expand execut complement pipelin pt
em dcf analysi use discount rate termin growth rate convert impli
market cap eur usd use month fx averag /em
may dova pdufa avatrombopag thrombocytopenia chronic liver
fda accept avatrombopag nda prioriti review treatment
thrombocytopenia patient chronic liver diseas cld schedul undergo
presum regul valid dova high degre confid
approv applic basi trial well studi
conduct indic
compani plan immedi launch june approv begun hire
key sale staff includ head us sale deep experi liver diseas drug
dova also remain track complet regulatori submiss ema approv
indic
addit cld indic dova explor label expans opportun broader
pre-surgeri popul thrombocytopenia patient chemotherapy-induc
dova believ opportun tripl size avatrombopag address market
may pdufa peg-pal pegvalias phenylketonuria pku
management remain optimist posit outcom fda convey
peg-pal pku shown lower blood phenylalanin amino acid accumul
pt phase studi
think neurocognit data requir fda registr base
discuss agenc
initi induction/titr phase like translat lower revenu per patient
management note meaning reduct phe consequ well ast
adult pt popul could lead attract market opportun almost sale
price releas upon approv management guid modest premium
ahead may pdufa management appear cautiou potenti launch
highlight lower dose use initi lower revenu per pt pegvalias
revenu may limit downsid impact revenu guidanc
yet pku clinic alreadi experienc pegvalias via clinic trial initi
physician pt feedback presum could help investor better project
june american societi clinic oncolog -- link titl note
earlier present interim clinic data phase ii studi margetuximab
plu mrk keytruda patient advanc line gastric cancer
expand studi enrol addit gastric cancer patient
compani present updat clinic biomark data year june
assign valu probability-weight sale margetuximab
gastroesophag cancer forecast sale
year meet updat patient treat combin
lead candid mirvetuximab soravtansin avastin
result includ data dose-expans cohort -- patient
avastin-na previous receiv avastin
line treatment set avastin-na pt avastin previous gener
median progression-fre surviv mpf chemotherapi well
expect report preliminari updat first clinic data micro-
dystrophin candid day june
earn call management establish threshold accept micro-dystrophin
express suggest would repres clear success
versu eteplirsen exon skip-amen duchenn muscular dystrophy/dmd
golodirsen exon dystrophin express level higher
could confer robust function clinic benefit pt
preclin data particular gene therapi construct present although
note lower dose sarepta/genethon construct produc express
lower dose solid bioscienc construct produc express dmd
dog think good potenti upsid home run level set
one three compani develop microdystrophin gene therapi dmd
competit acquir bamboo op solid clinic hold still
place sarepta could potenti first-to-mkt
continu await product approv expect
delay believ ttoo long-term outlook depend approv
convers manag suggest fda approv near june time-fram
believ earli demand propos quarter indic
interest
given expect market clearanc expect ttoo add addit
sale rep order penetr hospit rep today ou
manag indic sale forc focus sell total solut rather
candida view appear fundament chang
remain unconvinc ttoo sale execut would like see
approv follow solid sale pickup soon
expect topic jak inhibitor ph ii top-lin data alopecia areata
aa us studi patient one month durat could demonstr
earli valid topic jak inhibitor approach
also develop topic jak janu kinas inhibitor patchi hair loss
possibl androgenet alopecia aga aka male/femal pattern bald
success would open anoth multi-billion dollar market
compani jak inhibitor program treatment immune-medi hair loss
disord aa core upsid driver model account
even use conserv assumpt believ oral jak inhibitor could achiev peak
annual sale aa alon
ph ii top-lin data australia eyebrow studi patient
next import catalyst alder six month data ph pivot trial
chronic migrain due second quarter
trial expect provid extend durat repeat dose safeti efficaci
month
data expect includ bla eptinezumab need
consist earlier announc data free increas new
advers event increas neutral antibodi
celg ph trial revlimid follicular lymphoma
augment trial approach complet top-lin result releas mid-
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
continu optimist ahead pdufa given step taken scph
mitig potenti review risk
manag see signific opportun furoscix reduc patient admiss day
hospit acceler patient discharg reduc readmiss rate
continu believ furoscix subcutan administr gain strong earli
adopt hospital-bas event drive iv furosemid use market
iv diuresi iv furosemid
believ furoscix provid strong pharmacoeconom incent move care
high cost hospit set at-hom set
continu see odd success approv forecast
sale sale
initi furoscix heart failur health econom outcom research studi
june akao pdufa plazomicin gram neg infect
decemb akao report posit top-lin data two phase studi epic
expect support registr expect primari driver
commerci adopt
epic recruit patient suspect complic urinari tract infect cuti
demonstr plazomicin statist non-inferior meropenem fda primari
endpoint statist superior three key efficaci measur includ ema
primari outcom test cure
see nich role plazo treatment-refractori cuti expect drug
primari clinic util carbapenem-resist enterobacteriacea support
compel data studi albeit small sampl show
reduct death/seri complic mortal respect rel
activ control
continu project peak sale plazomicin ww us sale
row royalti us sale come base upon trajectori
agn avycaz accord medacorp kol gener major sale
off-label use infect
despit regulatori process drag manag re-affirmed confid
april investor day see link takeaway approv ahead june
criteria demonstr same appear rigor respond
everi inform request fda issu point believ
outstand scientif issu product
manufactur gener begun compani would readi launch
new product launch key offset continu pressur us gener
kol specialist takeaway link global healthcar confer support
view obtain approv like see limit competit
estim gener advair revenu
account potenti competitor delay
announc final patient dravet studi complet dose
may expect report top-lin data trial late june earli juli
dravet syndrom present signific unmet medic need compel clinic
data first two dravet studi render investor physician
patient excit potenti drug
initi phase studi demonstr unpreced level seizur
reduct dravet patient
initi roll nda base result two phase dravet
studi data avail open-label extens suffici
patient exposur support safeti requir file
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
one regn import catalyst approv antibodi cemiplimab
cutan squamou cell carcinoma cscc
compani pdufa date octob research suggest first approv
checkpoint antibodi new indic typic come ahead pdufa date like
june juli cemiplimab estim
particularli true applic benefit breakthrough design
prioriti review case cemiplimab
regeneron also appear signal expect approv occur earlier
date confirm us commerci team readi launch product
immedi avail channel
project peak pos-adjust us cemiplimab sale
june present updat analysi pivot
cscc studi focus cemiplimab long-term activ durabl suggest
may addit data studi indic meet
fda approv eversens implant cgm diabet
expect secur fda approv eversens continu glucos
monitor cgm believ nearli total address market
us alon
view eversens appeal broad patient popul encompass
type current declin cgm option due high burden therapi
patient also type reason
alreadi receiv approv eversens eversens xl
europ eversens xl launch uk sweden expect
transit eversens xl europ market
regard us product launch current employe us
commerci team -- readi launch eversens upon fda approv --
compani plan doubl team
fda panel vote unanim favor cgm approv march
believ us approv question
near term secur fda approv eversens time dose claim
like next major catalyst stock
current project us eversens sale
near term secur fda approv eversens time dose claim
like next major catalyst stock
sourc leerink research compani inform factset price prior day
pdufa dova avatrombopag thrombocytopenia chronic liver diseas
fda adcom joint anesthet analges drug product drug safeti
fda ad\com anesthesiolog respiratori therapi devic
pdufa akao plazomicin complic urinari tract infect bloodstream
medcac panel procedur volum requir hospit heart team
member begin maintain transcathet aortic valv replac
medcac panel t-cell therapi
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa revefanacin lama copd
societi neurolog surgeon
world feder hemophilia
ph phoenix bardoxolon data renal diseas adpkd lgan link note
european academi allergi clinic immunolog dbvt
american societi clinic psychopharmacolog
american colleg sport medicin
european feder nation associ orthopaed traumatolog
societi imag informat medicin
american societi clinic oncolog adap armo celg
american societi transplant surgeon
american societi neuroradiolog
american societi mass spectrometri
american societi microbiolog
associ profession infect control epidemiolog
european hematolog associ link note abstract arql
european academi neurolog
complex cardiovascular cathet advanc endovascular
feder clinic immunolog societi
intern societi stem cell research
societi vascular surgeri
societi nuclear medicin molecular imag
model model univers coverag
-- flash aducanumab phase trial expand variabl endpt requir
-- flash takeaway leerink global healthcar confer
 growth margin management stabil still lack pipelin catalyst market
 aducanumab titrat arm bolster evid treatment effect market perform
 ctad medacorp call aducanumab abeta hypothesi
life scienc tool diagnost -- flash fund present posit upsid nih
spend life scienc tool
 leerink confer highlight dinner manag market
 apec studi discontinu remov verubecestat model pt market
 state larg cap biotech sfo steadi goe
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 ttr seri part handicap on-going tafamidi trial fac market
 growth deal capac target market
 set new slow-growth outlook get excit pt
biopharma praluent show mortal benefit lower take aim highest risk group
biopharma -- flash highlight invokana fda warn puls call modest impact
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
novob dc evolut market make pivot year novo
 aet creat new front healthcar outperform larsen david
manag cvs-aet neutral ep wcg ci
gupt ana
biopharma -- flash highlight invokana fda warn puls call modest impact
medic devic leerink healthcar confer panel devic penetr set
medic devic ada wrap-up posit meet devic podd/abt/mdt
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
novob dc -- flash near-unanim vote clear path semaglutid approv
 upgrad op convict top-lin growth accel stori pt
 ar takeaway -- -excit build ahead sinuva launch outperform
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
hcit distribut fda take step improv competit distributor near trough
 acthar survey suggest faster eros payer pressur competitor entri
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
biopharma -- flash highlight io combin seri puls call front-lin lung
biopharma highlight io agonist checkpoint puls call updat
io clinic trial updat crossroad effici
 deep dive highlight oncolog focu strategi nash market perform
achn recap increment advanc patent complement progress
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
biopharma cafc oral argument justic challeng scope ab patent
 patent issuanc reflect execut strategi pt outperform
 investor sleep path ip protect pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
 quiet focu remain pot ibs-c partnership catalyst outperform
biopharma might deton event look like screen pot match-
biopharma viii partnership acquisit biopharma new top list
celg anoth bet car-t probabl probabl sensibl even
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 add cscc respons diseas boost /sni partnership
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
 initi adama step forward parkinson dyskinesia outperform
 atop dermat still without ped leerink dupix
derm survey
 hiv survey rapid adopt biktarvi challeng outlook
gsk
 initi
moat vs
 insight april nyc hc servic day convict
medic suppli devic survey direct posit
mute hope new indications/improv execut
 mylan upgrad valuat disconnect given diversifi busi catalyst
path outperform
 initi could adenosin inhibit unlock wave i/o
outperform
 come-back stori make survey support opu market
share assumpt outperform
 initi doubl digit growth meaning margin expans ahead
outperform
-- contact leerink repres detail access podcast
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
 pnh survey-soliri still grow like switch monthli sc best
biopharma atop derm still without ped leerink dupi derm survey
 pbc survey suggest ocaliva safeti concern manag
 hiv survey rapid adopt biktarvi challeng outlook
 rubraca posit base survey lower est due payer assist
hcit distribut demand shift analyt effect use
 vyxeo survey suggest outpati usag grow outperform
major medacorp survey lung cancer posit azn
limit upsid link
medic suppli devic survey flu help otherwis normal volume downtick
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
medic devic survey direct posit mute hope
tsro ovarian cancer survey affirm parp market upgrad op improv risk/
 leerink leadership seri new product growth acceler stori market
medic devic leerink leadership seri outset drive shift dialysi self-car
medic devices-cardiolog leerink leadership seri target
outlook alpha opportun abound healthcar share
